In a man with ETV6-NTRK3 fusion parotid cancer on larotrectinib, withdrawal-like myalgias, arthralgias and light sensitivity resolved completely after he started semaglutide.
In plain wordsIn one man on larotrectinib, muscle and joint symptoms between doses went away after he started semaglutide. One case cannot show cause.
- Peptide
- Semaglutide
- Outcome
- DecreaseResolution of larotrectinib withdrawal-like symptoms
- Study
n = 1
- Outcome group
- Pain · Musculoskeletal
- Studied dose
- Dose not stated
Source sentences
This continued until he was started on semaglutide, a GLP-1 receptor agonist, after which his symptoms completely resolved.
2 context sentences(design, population, supporting numbers)
A 35-year old male with metastatic/recurrent ETV6-NTRK3 fusion parotid gland cancer was enrolled on a clinical study investigating the efficacy of larotrectinib.
Early after starting therapy he experienced twice a day diffuse myalgias, arthralgias, and light sensitivity starting 30 to 45 min before his next dose was due.